Vicarious Surgical Narrows Loss in Q2
Vicarious Surgical (NYSE:RBOT), a developer focused on next-generation robotic technology for minimally invasive surgery, released its second quarter 2025 financial results on August 12, 2025. The standout news: the company posted a narrower non-GAAP net loss than analysts anticipated, with an EPS (Non-GAAP) loss of $2.23 versus the forecasted $2.50. Operating expenses dropped across all categories, supporting cost control efforts. Still, no revenue was reported, reinforcing its ongoing pre-commercial status. With cash and investments falling to $24.0 million and continued cash burn, the company faces important milestones and funding needs ahead as it works toward regulatory approval and future commercialization.
Source: Analyst estimates for the quarter provided by FactSet.
Vicarious Surgical is developing a surgical robot aimed at enabling minimally invasive procedures through a single small incision. Its flagship product, the Vicarious Surgical System, is designed to increase dexterity, improve visualization for surgeons, and streamline operating room workflow. The company’s key objective is to secure U.S. Food and Drug Administration (FDA) authorization for its system so it can begin selling in the United States, initially targeting ventral hernia repairs.
Source Fool.com
